Company / Net Income
Neurocrine Biosciences Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$478.6M
FY2025
5-year range
$89.6M / $478.6M
FY2021-FY2025
Trend
+40.2%
vs FY2024
Sector context
#21 of 216
Health Care
What the data says
Among 216 Health Care companies, Neurocrine Biosciences is in the top 10% for net income. Net Income has fluctuated over the past 10 years, ranging from -$143M in FY2017 to $479M in FY2025.
Based on SEC 10-K filings.
$479M in FY2025 with a 5-year CAGR of +3.3%. Top quartile in the Health Care sector.
Improved from $250M to $479M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- +5.5%
- 5-Year CAGR
- +3.3%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 216This company $478.6M Sector average $454.1M
▼
+5.4% above sector average
Key checks
Key Insights
- 5-year CAGR of +3.3%, indicating consistent growth.
- In FY2025, net income increased 40.2% year-over-year.
- Ranks #21 out of 216 companies in the Health Care sector.
- Lowest net income in the period was in FY2017.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $478.6M | +40.2% |
| FY2024 | $341.3M | +36.7% |
| FY2023 | $249.7M | -38.7% |
| FY2022 | $407.3M | +354.6% |
| FY2021 | $89.6M | -78.0% |
| FY2020 | $407.3M | +1000.8% |
| FY2019 | $37.0M | +75.4% |
| FY2018 | $21.1M | +114.8% |
| FY2017 | -$142.5M | -1.0% |
| FY2016 | -$141.1M | -58.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026